Teva Highlights Long-term Success of Deutetrabenazine for TD
Teva Highlights Long-Term Success of Deutetrabenazine for Tardive Dyskinesia
In a significant revelation, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced that its treatment, deutetrabenazine, demonstrates remarkable long-term efficacy and safety for patients with Tardive Dyskinesia (TD). This information comes from the European cohort of the RIM-TD open-label extension (OLE) study, showing consistent improvements in TD symptoms over a three-year period.
Understanding Tardive Dyskinesia
Tardive Dyskinesia is a troubling involuntary movement disorder that arises in approximately 15% to 25% of patients who are undergoing antipsychotic treatment for various mental health disorders, including schizophrenia and bipolar disorder. The disorder often leads to repetitive and involuntary movements that can be socially stigmatizing and debilitating, greatly impacting the quality of life for affected individuals.
The RIM-TD Study and Its Findings
The RIM-TD study represents a comprehensive analysis involving patients who had previously participated in various deutetrabenazine phase 3 trials, specifically the ARM-TD and AIM-TD studies. During this long-term study, treatment success was defined as either 'much improved' or 'very much improved' based on standardized global assessments. Impressively, 65% of participants met this benchmark using the Clinical Global Impression of Change (CGIC), while 56% did so according to the Patient Global Impression of Change (PGIC).
Positive Feedback from Experts
At the recent European College of Neuropsychopharmacology Congress in Milan, Dr. Krzysztof Duma, who is Teva's Associate Medical Director, highlighted the complexities surrounding the diagnosis and treatment of Tardive Dyskinesia. He stated that the study's positive outcomes within the European cohort were consistent with previous findings in the overall population, providing valuable evidence that deutetrabenazine can be a viable treatment option.
The Importance of Effective Treatment
Managing TD presents a unique challenge, as many treatments in Europe lack robust clinical evidence and are frequently used off-label. Patients often undergo dose reductions of their antipsychotic medication in an effort to alleviate TD symptoms, which can inadvertently worsen their underlying psychiatric condition.
The Call for Better Management Practices
Pinar Kokturk, M.D., Vice President & Head of Medical Affairs at Teva, underscored the urgent need for optimized treatment strategies for Tardive Dyskinesia, citing the lack of comprehensive guidelines across Europe. The call to action stresses that clinical practices must evolve to address the high unmet needs associated with TD, ultimately improving patient outcomes.
Conclusion: The Future of Tardive Dyskinesia Treatment
With established approval in the United States and various international markets, deutetrabenazine has exhibited noteworthy benefits in improving motor functions in patients suffering from Tardive Dyskinesia across extensive research studies, including ARM-TD and AIM-TD. This treatment not only addresses the immediate symptoms of TD but also aligns with Teva's mission to enhance the overall health experiences of patients.
Frequently Asked Questions
What is Tardive Dyskinesia?
Tardive Dyskinesia is a chronic disorder characterized by involuntary, repetitive movements often resulting from long-term use of antipsychotic medications.
What is deutetrabenazine?
Deutetrabenazine is a medication specifically designed to treat Tardive Dyskinesia by inhibiting the vesicular monoamine transporter type 2 (VMAT2), which helps reduce abnormal movements.
How effective is deutetrabenazine in treating TD?
In clinical studies, deutetrabenazine has shown long-term improvements in TD symptoms, with a majority of patients experiencing significant relief throughout the treatment duration.
Where can I find more information about Teva’s products?
Additional information on Teva Pharmaceutical Industries and its range of medications can be found on their official website.
What sets the RIM-TD study apart?
The RIM-TD study uniquely focuses on European patients who previously participated in pivotal phase 3 trials, providing targeted insights into the treatment effects of deutetrabenazine.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Rivian Automotive: Navigating Challenges Towards Success
- Fuji Soft's Decision Amidst Competing Offers Explained
- Tesla Confirms High Efficiency of Inductive Charging for Cybercab
- Exploring High-Yield Investments for Steady Income Growth
- US Government Probes Unauthorized Disclosure of Classified Intel
- Important Class Action Update for Sage Therapeutics Investors
- Investor Alert: Key October Deadline for STMicroelectronics Case
- Discover Yingtan: The Heart of Copper Industry Growth
- Why Investors are Optimistic About the Future of the S&P 500
- Investing in Dividend Stocks: A Guide for Retirement Planning
Recent Articles
- Innate Pharma Gears Up for Phase 1 Study of IPH4502 in Cancer
- Faraday Future Partners with Born Leaders to Showcase FF 91 2.0
- Global ERP Market Projected to Hit $117.09 Billion by 2030
- Revolutionizing Hospitality: Insights from Katch and Keane
- Global QR Code Payment Market Set to Surge by 2030
- Gold Prices Surge to New Heights Amid Rate Cuts and Optimism
- Global Markets Anticipate Rate Cuts Amid Economic Shifts
- Soaring Gold Prices: Stability Amid Global Uncertainties
- Bitcoin Surges as Fed Cuts Spark Currency Reactions
- Dignitaries Unite in New York to Combat Child Violence
- Jony Ive and Sam Altman Unite for Revolutionary AI Device
- Miracle Journey of Rayne Beau: A Cat's 900-Mile Return Home
- Wego Partners with Malaysia Airlines for Enhanced Travel Access
- Anthony Scaramucci Highlights Solana's Potential in Finance
- Wego Partners with Malaysia Airlines to Enhance Travel Choices
- Japan and China Strengthen Ties Amidst Security Concerns
- Aviat Networks Faces Scrutiny Amid Reports of Delayed Filings
- Uber's Strategic Growth: Financial Insights and Market Impact
- Analyzing Recent Trends and Potential Future Moves in Crypto
- Avicena Unveils Groundbreaking 30m MicroLED Connectivity Technology
- Shaquille O'Neal Clarifies Mishap with Tim Walz's Restaurant Visit
- Shiba Inu's Burn Rate Surges, Community Seeks Faster Action
- Dunhuang Silk Road Expo: A Celebration of Global Cultural Ties
- Samsung's Bold $1.8 Billion Leap for OLED In Vietnam's Market
- Huawei Unveils Advanced AI Medical Solution for Healthcare
- Unveiling Data Center Asia 2025: A Gateway to Innovation
- Interest Rate Reforms Stalled as Greens Push for Cuts
- RBA Holds Steady in September, Signals Long-Term Hawkish Stance
- BYD's Plans for EV Assembly in Pakistan Amidst Global Expansion
- In-Depth Insights into Vertex Pharmaceuticals' Market Position
- Nokia Upgrades IGC's Network with Advanced DWDM Technology
- Lindsey Graham Urges Shift in Middle East Tactics for Stability
- Market Shifts: Bitcoin Surges While Dogecoin Declines Amid Crypto Buzz
- TSMC and Samsung's Ambitious Plans for Chip Factories in UAE
- Huawei Unveils Solution for ICT Talent Development and Smart Campus
- Consumer Watchdog Targets Major Supermarkets in Australia
- Asian Stock Markets React to Rate Cuts and Retail Troubles
- Markor Transforms Home Living with Innovative AI Strategies
- China's Central Bank Takes Steps to Ease Monetary Conditions
- China's Economic Strategies: Insights and Future Prospects
- Exciting Highlights from the Successful 2024 Marathon Event
- CRRC's Innovative Solutions for Sustainable Rail Transport
- Source Photonics Introduces Advanced 1.6T and 800G PAM4 Solutions
- Bernie Sanders Highlights High Costs of Ozempic and Patient Impact
- Oil Prices Surge amid Middle East Tensions and Economic Shifts
- Walmart's Strategic Innovations and Market Resilience: A Deep Dive
- McLaren F1 Team Celebrates Podium Finish with Iconic Livery
- Conexus MedStaff Boosts Education for Youth in the Philippines
- Perplexity AI Collaborates with Nike and Marriott: A New Search Era
- Discover the Revolutionary TECNO SPARK 30 Series Smartphones